Literature DB >> 15151524

Relationship between Type A and B personality and debrisoquine hydroxylation capacity.

S H Gan1, R Ismail, W A Wan Adnan, W Zulmi, N Kumaraswamy, E T Larmie.   

Abstract

AIM: A person with Type A personality is an 'aggressor' compared with the rarely harried Type B. Although debrisoquine hydroxylase (CYP2D6) capacity has been associated with personality, no study has specifically investigated its association with personality Type A and B. Therefore the aim of this research was to study the impact of CYP2D6 on Type A and B personality.
METHODS: Type A and B personality questionnaires were administered to 48 healthy patients undergoing elective orthopaedic surgery. After obtaining informed consent, patients were genotyped for the various CYP2D6 alleles by allele-specific polymerase chain reaction. Based on the genotypes, patients were grouped as extensive metabolizer (EM)1 (normal) (CYP2D6*1/*1), EM2 (intermediate) (CYP2D6*1/*4, CYP2D6*1/*5, CYP2D6*1/*9 and CYP2D6*1/*10) and EM3 (slow) (CYP2D6*4/*10, CYP2D6*5/*10, CYP2D6*10/*10 and CYP2D6*10/*17). Chi(2) was used to determine the relationship between the groups and personality types.
RESULTS: The percentages of patients who were of the EM1, EM2 and EM3 groups were 20.8%, 52.1% and 27.1%, respectively. There was a significant difference (P = 0.032) between the three groups in terms of personality type, in which EM1 showed a tendency to be of personality Type A while EM2 and EM3 tended to be of personality Type B.
CONCLUSION: The study suggests that there is a relationship between CYP2D6 activity and Type A and B personality.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15151524      PMCID: PMC1884512          DOI: 10.1111/j.1365-2125.2004.02076.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  Heterogeneity of the CYP2D6 gene among Malays in Malaysia.

Authors:  L K Teh; R Ismail; R Yusoff; A Hussein; M N Isa; A R Rahman
Journal:  J Clin Pharm Ther       Date:  2001-06       Impact factor: 2.512

Review 2.  Interethnic variation of drug metabolism.

Authors:  W Kalow
Journal:  Trends Pharmacol Sci       Date:  1991-03       Impact factor: 14.819

Review 3.  Cytochromes P450 and metabolism of xenobiotics.

Authors:  P Anzenbacher; E Anzenbacherová
Journal:  Cell Mol Life Sci       Date:  2001-05       Impact factor: 9.261

4.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

Authors:  M Heim; U A Meyer
Journal:  Lancet       Date:  1990-09-01       Impact factor: 79.321

5.  Debrisoquine hydroxylation polymorphism and personality.

Authors:  L Bertilsson; C Alm; C De Las Carreras; J Widen; G Edman; D Schalling
Journal:  Lancet       Date:  1989-03-11       Impact factor: 79.321

6.  Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population.

Authors:  M Garcia-Barceló; L Y Chow; H F Chiu; Y K Wing; D T Lee; K L Lam; M M Waye
Journal:  Clin Chem       Date:  2000-01       Impact factor: 8.327

7.  Sample size calculations for clinical pharmacology studies.

Authors:  P D Stolley; B L Strom
Journal:  Clin Pharmacol Ther       Date:  1986-05       Impact factor: 6.875

8.  A short rating scale as a potential measure of pattern A behavior.

Authors:  R W Bortner
Journal:  J Chronic Dis       Date:  1969-07

9.  Oxidation phenotyping in Chinese and Malay populations.

Authors:  E J Lee; Y P Nam; G N Hee
Journal:  Clin Exp Pharmacol Physiol       Date:  1988-11       Impact factor: 2.557

10.  Markers for vulnerability to psychopathology: temperament traits associated with platelet MAO activity.

Authors:  D Schalling; M Asberg; G Edman; L Oreland
Journal:  Acta Psychiatr Scand       Date:  1987-08       Impact factor: 6.392

View more
  4 in total

Review 1.  CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials.

Authors:  Eva M Peñas-Lledó; Adrián Llerena
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

Review 2.  Transcriptional Regulation of CYP2D6 Expression.

Authors:  Xian Pan; Miaoran Ning; Hyunyoung Jeong
Journal:  Drug Metab Dispos       Date:  2016-10-03       Impact factor: 3.922

3.  Potential role of CYP2D6 in the central nervous system.

Authors:  Jie Cheng; Yueying Zhen; Sharon Miksys; Diren Beyoğlu; Kristopher W Krausz; Rachel F Tyndale; Aiming Yu; Jeffrey R Idle; Frank J Gonzalez
Journal:  Xenobiotica       Date:  2013-04-25       Impact factor: 1.908

4.  Fatal intoxication cases: cytochrome P450 2D6 and 2C19 genotype distributions.

Authors:  A L Zackrisson; P Holmgren; A B Gladh; J Ahlner; B Lindblom
Journal:  Eur J Clin Pharmacol       Date:  2004-09-02       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.